Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to Taxol

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Zhou, Ming ^a,b   Zhao, Yuhua ^a   Ding, Yan ^a   Liu, Hao ^a   Liu, Zixing ^a   Fodstad, Oystein ^a,c   Riker, Adam I ^a,e   Kamarajugadda, Sushama ^d   Lu, Jianrong ^d   Owen, Laurie B ^a   Ledoux, Susan P ^a   Tan, Ming ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF FLORIDA   (United States)

^e Ochsner Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ISOENZYME 5; OXAMIC ACID; PACLITAXEL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ISOENZYME; LACTATE DEHYDROGENASE 5;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL GROWTH; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; RNA INTERFERENCE; BREAST TUMOR; DOWN REGULATION; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE SILENCING; GLYCOLYSIS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; GENE KNOCKDOWN TECHNIQUES; GLYCOLYSIS; HUMANS; ISOENZYMES; L-LACTATE DEHYDROGENASE; PACLITAXEL;

EID: 77649094375     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-33     Document Type: Article

References (32)

1. Henley D, Isbill1 M, Fernando1 R, Foster1 JS, Wimalasena1 J. Paclitaxel induced apoptosis in breast cancer cells requires cell cycle transit but not Cdc2 activity. Cancer Chemother Pharmacol 2007, 59(2):235-249. 10.1007/s00280-006-0262-1, 16972069.
2. Tan M, Yu D. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol 2007, 608:119-129. full_text, 17993237.
3. Frankel A, Buckman R, Kerbel RS. Abrogation of Taxol- induced G2-M Arrest and Apoptosis in Human Ovarian Cancer Cells Grown as Multicellular Tumor Spheroids. Cancer Res 1997, 57:2388-2293.
4. Chen LP, Cai SM, Fan JX, Li ZT. PEBA Regimen (Cisplatin, Etoposide, Bleomycin, and Adriamycin) in the Treatment of Drug-Resistant Choriocarcinoma. Gynecologic Oncology 2002, 56(2):231-234.
5. Donnenberg VS, Donnenberg AD. Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis. J Clin Pharmacol 2005, 45:872-877. 10.1177/0091270005276905, 16027397.
6. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993, 62:385-427. 10.1146/annurev.bi.62.070193.002125, 8102521.
7. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997, 100(5):1282-1293. 10.1172/JCI119642, 508306, 9276747.
8. Panda D, Miller HP, Banerjee A, Ludueña RF, Wilson L. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci USA 1994, 91(24):11358-11362. 10.1073/pnas.91.24.11358, 45230, 7972064.
9. Martello LA, Verdier-Pinard P, Shen HJ, He L, Torres K, Orr GA, Horwitz SB. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res 2003, 63(6):1207-1213.
10. Gonçalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S, Wilson L, Jordan MA. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci 2001, 98:11737-11741. 10.1073/pnas.191388598, 58799, 11562465.
11. Tan M, Jing T, Lan KH, Neal CL, Li P, Lee S, Fang D, Nagata Y, Liu J, Arlinghaus R, Hung MC, Yu D. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell 2002, 9:993-1004. 10.1016/S1097-2765(02)00510-5, 12049736.
12. Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, Su XH, Yang WT, Treekitkarnmongkol W, Andreeff M, Symmans F, Yu D. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res 2009, 15(4):1326-1334. 10.1158/1078-0432.CCR-08-0954, 19228734.
13. Warburg O. On respiratory impairment in cancer cells. Science 1956, 124:269-270.
14. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006, 66:8927-8930. 10.1158/0008-5472.CAN-06-1501, 16982728.
15. Chen Z, Lu W, Garcia-Prieto C, Huang P. The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 2007, 39(3):267-274. 10.1007/s10863-007-9086-x, 17551814.
16. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9:425-434. 10.1016/j.ccr.2006.04.023, 16766262.
17. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999, 24:68-72. 10.1016/S0968-0004(98)01344-9, 10098401.
18. Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu DH, Fodstad O, Tan M. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene 2009, 28:3689-3701. 10.1038/onc.2009.229, 19668225.
19. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993, 53(17):3976-3985.
20. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, Smulson M. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 1999, 274(33):22932-22940. 10.1074/jbc.274.33.22932, 10438458.
21. Chang GG, Huang SM, Chiou SH. Kinetic mechanism of the endogenous lactate dehydrogenase activity of duck epsilon-crystallin. Arch Biochem Biophys 1991, 284(2):285-291. 10.1016/0003-9861(91)90297-V, 1989512.
22. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008, 7:11-20. 10.1016/j.cmet.2007.10.002, 18177721.
23. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13:472-482. 10.1016/j.ccr.2008.05.005, 18538731.
24. Gorlach A, Acker H. pO2- and pH-gradients in multicellular spheroids and their relationship to cellular metabolism and radiation sensitivity of malignant human tumor cells. Biochim Biophys Acta 1994, 1227:105-112.
25. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, Linehan WM, Sukhatme VP, Seth P. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Molecular Cancer Therapeutics 2009, 8(3):626-635. 10.1158/1535-7163.MCT-08-1049, 19276158.
26. Vaughn1 AE, Deshmukh M. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat Cell Biol 2008, 10(12):1477-1483. 10.1038/ncb1807, 2626347, 19029908.
27. Basu A, DuBois G, Haldar S. Posttranslational modifications of Bcl2 family members--a potential therapeutic target for human malignancy. Front Biosci 2006, 11:1508-1521. 10.2741/1900, 16368533.
28. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994, 78:539-42. 10.1016/0092-8674(94)90518-5, 8069905.
29. Thornburg JM, Nelson KK, Clem BF, Lane AN, Arumugam S, Simmons A, Eaton JW, Telang S, Chesney J. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res 2008, 10(5):R84. 10.1186/bcr2154, 2614520, 18922152.
30. Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB, Yu D. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 2004, 64:3479-3485. 10.1158/0008-5472.CAN-3299-2, 15150101.
31. Welch DR. Technical considerations for studying cancer metastasis in vivo. Clin Exp Metastasis 1997, 15:272-306. 10.1023/A:1018477516367, 9174129.
32. Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?. Cancer Res 2009, 69(13):5292-5293. 10.1158/0008-5472.CAN-09-1528, 19549886.